G. Ferron (a), L. Klumpers (b), Joop van Gerven(b), and C. Roy (a) PK and PK/PD modeling of CB1 blocker antagonism of THC induced CNS and Heart Rate effect
|
Brigitte Lacroix(1), Philipp von Rosenstiel(2), Maria Laura Sargentini-Maier(1) Population Pharmacokinetics of Brivaracetam in Patients with Partial Epilepsy
|
O. Lillin-de Vries, T. Kerbusch, P-J. de Kam, N. Ivgy-May, R. Bursi A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers.
|
Rik de Greef (1), Lena E. Friberg (2), Sunny Chapel (3), Matthew M. Hutmacher (3), Marita Prohn (1), Alan Maloney (4), Thomas Kerbusch (1), Mats O. Karlsson (2), Carl C. Peck (5) Modeling and Simulation to Integrate Efficacy and Safety Data Following Full Development: a Case Study in Schizophrenia and Bipolar Disorder
|
Bart Laurijssens1, Andreas Krause2, Lutz Harnisch3 Model-Based Analysis of a Longitudinal Binary Response as the Primary Analysis for a Phase II Study in Migraine Prophylaxis.
|
Kaori Ito*, Matt Hutmacher#, Jing Liu, Ruolun Qiu, Bill Frame, Raymond Miller Exposure-Response Analysis of Longitudinal Adverse Event Data.
|
Sarah McLeay, Glynn Morrish, Carl Kirkpatrick & Bruce Green Scaling propofol doses for the obese: is lean body weight the answer?
|
Guangli Ma, Lena E. Friberg, Mats O. Karlsson Pool Model versus Agonist-Antagonist Interaction Model for the Remoxipride Effect on Prolactin
|
I. Locatelli(1), M. Kastelic(2), J. Koprivsek(3), B. Kores-Plesnicar(3), A. Mrhar(1), V. Dolzan(2), I. Grabnar(1) Population Pharmacokinetics of Risperidone in Patients with Acute Schizophrenia
|
K. Vucicevic(1), B. Miljkovic(1), M. Pokrajac (1), I. Grabnar(2) Estimation of Relative Bioavailability of Controlled-Release Carbamazepine Tablets Based on Routine TDM Data
|
Bizzotto R (1), Zamuner S (2), Nucci G (2), Cobelli C (1), Gomeni R (2) Mixed Effects Markov Models for Modelling Sleep in Insomniac Patients Treated with Placebo in a 28 Days Trial: Emphasis on the Break Points Selection
|
Gianluca Nucci (1), Ana M. Catafau (2), María M. Penengo (3), Santiago Bullich (3), Emilio Merlo-Pich (2) and Roberto Gomeni (1) A sparse sample PK & PKPD approach to estimate the time course of antipsychotic-induced D2 occupancy
|
S.Gisbert, B. Laurijssens, C. Chen Analysing Raw Count data from an In Vitro Target Occupancy Assay to Select Doses for Human Safety/Tolerability Trial
|
Elba Romero E1, Juan Fernández-Candil2, Pedro L. Gambús2, Ricardo Valero2, Enrique Carrero2, Lorea Bueno1, Neus Fábregas2, Iñaki F. Trocóniz1 Extended Link Model to Describe the Impact of Chronic Antiepileptic Therapy on the Effects of Neuromuscular Blocking Agents.
|
M. Simeoni(1), C. Chen(1), P. Dua(2), R.E. Oliver-Willwong (1), D. J. Austin(1) Modelling beta amyloid system: sensitivity analysis at steady state and in dynamic conditions.
|
Alienor Berges(1), Stefano Zamuner(2), Bart Laurijssens(1), Roger Gunn(3), Vincent Cunningham(3), Chao Chen(1) Using VT (total volume of distribution from PET) in estimating the PK-Receptor Occupancy relationship in the absence of reference regions.
|
Debra Tompson, Ruth Oliver-Willwong, Chao Chen Population modeling of the relationship between ropinirole systemic exposure and efficacy in Parkinson’s disease
|
E. Snoeck (1), R. Schoemaker (1), A. Stockis (2), C. Otoul (2), M.L. Sargentini-Maier (2) Levetiracetam exposure-response analysis in children with partial onset seizures
|